Strong anti-Epstein Barr virus (EBV) or cytomegalovirus (CMV) cellular immune responses predict survival and a favourable response to anti-tuberculosis therapy

International Journal of Infectious Diseases

Volumn 56, Issue , 2017, Pages 136-139

  Nagu, Tumaini ^a,b   Aboud, Said ^b   Rao, Martin ^a   Matee, Mecky ^b   Axelsson, Rebecca ^b   Valentini, Davide ^b   Mugusi, Ferdinand ^b   Zumla, Alimuddin ^c   Maeurer, Markus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

cellular immune response; CMV; EBV; IFN ; pulmonary tuberculosis; survival; TB therapy

Indexed keywords

ANTIGEN; BACTERIAL PROTEIN; EARLY SECRETORY ANTIGENIC TARGET 6; ETHAMBUTOL; GAMMA INTERFERON; ISONIAZID; MYCOBACTERIUM ANTIGEN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; BCG VACCINE;

ADULT; ASSAY; BLOOD SAMPLING; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; INFLUENZA A VIRUS (H5N1); LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; SPUTUM SMEAR; SUPERNATANT; SURVIVAL; TREATMENT RESPONSE; VENOUS BLOOD; IMMUNOLOGY; MORTALITY; PREDICTIVE VALUE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ADULT; ANTITUBERCULAR AGENTS; CYTOMEGALOVIRUS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, CELLULAR; MALE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 85013794959     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2017.01.022     Document Type: Review

References (10)

1. 1 La Rosa, C., Diamond, D.J., The immune response to human CMV. Future Virol 7 (2012), 279–293.
2. 2 Jung, J., Munz, C., Immune control of oncogenic gamma-herpesviruses. Curr Opin Virol 14 (2015), 79–86.
3. 3 Zumla, A., Rao, M., Parida, S.K., Keshavjee, S., Cassell, G., Wallis, R., et al. Inflammation and tuberculosis: host-directed therapies. J Intern Med 277 (2015), 373–387.
4. 4 Terrazzini, N., Bajwa, M., Vita, S., Thomas, D., Smith, H., Vescovini, R., et al. Cytomegalovirus infection modulates the phenotype and functional profile of the T-cell immune response to mycobacterial antigens in older life. Exp Gerontol 54 (2014), 94–100.
5. 5 Pollock, K.M., Montamat-Sicotte, D.J., Cooke, G.S., Kapembwa, M.S., Kon, O.M., Grass, L., et al. Differences in antigen-specific CD4+ responses to opportunistic infections in HIV infection. Immun Inflamm Dis 3 (2015), 141–153.
6. 6 Bickham, K., Munz, C., Tsang, M.L., Larsson, M., Fonteneau, J.F., Bhardwaj, N., et al. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest 107 (2001), 121–130.
7. 7 Brodin, P., Rosenkrands, I., Andersen, P., Cole, S.T., Brosch, R., ESAT-6 proteins: protective antigens and virulence factors. Trends Microbiol 12 (2004), 500–508.
8. 8 Taggart, E.W., Hill, H.R., Ruegner, R.G., Litwin, C.M., Evaluation of an in vitro assay for interferon gamma production in response to the Mycobacterium tuberculosis-synthesized peptide antigens ESAT-6 and CFP-10 and the PPD skin test. Am J Clin Pathol 125 (2006), 467–473.
9. 9 WHO, Global Tuberculosis Report 2015., 2015, World Health Organization, Geneva p. 204.
10. 10 Zumla, A., Rao, M., Dodoo, E., Maeurer, M., Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med, 14, 2016, 89.